HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Neil A. Christie Thomas W. Rice Malcolm M. DeCamp Eugene H. Blackstone Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christie, N. A. Articles by Blackstone, E. H. Search for Related Content PubMed PubMed Citation Articles by Christie, N. A. Articles by Blackstone, E. H.

J Thorac Cardiovasc Surg 1999;118:900-907
© 1999 Mosby, Inc.

GENERAL THORACIC SURGERY

M1A/M1B ESOPHAGEAL CARCINOMA: CLINICAL RELEVANCE

From the Center for Swallowing and Esophageal Disorders, Department of Thoracic and Cardiovascular Surgery,^a Department of Anatomic Pathology,^b Department of Hematology and Medical Oncology,^c Department of Gastroenterology,^d and Department of Biostatistics and Epidemiology,^e The Cleveland Clinic Foundation, Cleveland, Ohio.

Address for reprints: Thomas W. Rice, MD, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195 (E-mail: ricet{at}ccf.org).

Objective: The 1997 staging system for esophageal carcinoma subdivides distant metastatic disease (M1) into M1a (nonregional lymph node metastases) and M1b (other metastases). This study evaluates the relevance of this classification.
Methods: One hundred forty patients were identified with M1 disease, 36 (26%) M1a and 104 (74%) M1b. The histologic type was adenocarcinoma in 118 (84%), squamous cell in 18 (13%), and adenosquamous in 4 (3%), with a similar distribution for M1a and M1b (P = .3). Forty-five underwent surgery, 28 (78%) with M1a disease and 17 (16%) with M1b disease (P < .001). Chemotherapy and/or radiation therapy was given to 33 (73%) surgical patients and 63 (66%) nonsurgical patients (P = .4), 28 (78%) with M1a disease and 68 (66%) with M1b disease (P = .17).
Results: Median and 5-year survivals were 11 months and 6% in patients with M1a disease and 5 months and 2% in those with M1b disease (P = .001). Surgery provided no advantage in M1b (P = .6) or M1a disease (P = .2). Multivariable analysis demonstrated that patients with M1b disease had 1.8 times the mortality risk of those with M1a disease (CI 1.2-2.7, P = .004), and patients without chemotherapy and/or radiotherapy had 2.2 times the mortality risk of those with chemotherapy and/or radiotherapy (CI 1.5-3.2, P < .001). Despite the prevalence of surgery in patients with M1a disease, the analysis suggests that M1a and use of chemotherapy and/or radiotherapy, rather than surgery, account for the small, clinically unimportant differences in survival.
Conclusions: We conclude that (1) although there are statistically significant survival differences between M1a and M1b disease, these differences are not clinically important; (2) chemotherapy and/or radiotherapy is associated with a modest survival benefit; and (3) surgery offers no survival advantage.

This article has been cited by other articles:

				P. C. Lee, J. L. Port, S. Paul, B. M. Stiles, and N. K. Altorki Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann. Thorac. Surg., July 1, 2009; 88(1): 186 - 193. [Abstract] [Full Text] [PDF]

				S. S. Lee, S.-B. Kim, S.-I. Park, Y. H. Kim, J.-S. Ryu, H.-Y. Song, J. H. Shin, H. Y. Jung, G. H. Lee, K. D. Choi, et al. Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 829 - 835. [Abstract] [Full Text] [PDF]

				S. C. Malaisrie, W. L. Hofstetter, A. M. Correa, J. A. Ajani, R. R. Komaki, Z. Liao, A. Phan, D. C. Rice, A. A. Vaporciyan, G. L. Walsh, et al. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 65 - 72. [Abstract] [Full Text] [PDF]

				T. W. Rice, E. H. Blackstone, D. J. Adelstein, G. Zuccaro Jr, J. J. Vargo, J. R. Goldblum, S. C. Murthy, M. M. DeCamp, and L. A. Rybicki Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1091 - 1102. [Abstract] [Full Text] [PDF]

				T. W. Rice, E. H. Blackstone, L. A. Rybicki, D. J. Adelstein, S. C. Murthy, M. M. DeCamp, and J. R. Goldblum Refining esophageal cancer staging J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1103 - 1113. [Abstract] [Full Text] [PDF]

				M. B. Wallace, P. J. Nietert, C. Earle, M. J. Krasna, R. H. Hawes, B. J. Hoffman, and C. E. Reed An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy Ann. Thorac. Surg., October 1, 2002; 74(4): 1026 - 1032. [Abstract] [Full Text] [PDF]

				K. S. Parmar, J. B. Zwischenberger, A. L. Reeves, and I. Waxman Clinical impact of endoscopic ultrasound-guided fine needle aspiration of celiac axis lymph nodes (M1a disease) in esophageal cancer Ann. Thorac. Surg., March 1, 2002; 73(3): 916 - 920. [Abstract] [Full Text] [PDF]

				M. A. Eloubeidi, M. B. Wallace, B. J. Hoffman, M. B. Leveen, A. Van Velse, R. H. Hawes, and C. E. Reed Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography Ann. Thorac. Surg., July 1, 2001; 72(1): 212 - 219. [Abstract] [Full Text] [PDF]

				R. K. Freeman and M. A. Wait Port site metastasis after laparoscopic staging of esophageal carcinoma Ann. Thorac. Surg., March 1, 2001; 71(3): 1032 - 1034. [Abstract] [Full Text] [PDF]